Email this article 
Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
- Authors: Semochkin S.V.1,2,3, Arshanskaya E.G.4,5,6, Zakharov O.D.7,8, Kotelnikova A.N.4,3, Kulikova S.S.1,2,3, Ovanesova E.V.9,10, Kochkareva Y.B.11,12, Ivanova V.L.13,6
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
- 1 Ostrovityanova St., Moscow, 117997, Russia Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow
- 1 Samory Mashela St., Moscow, 117198, Russia
- Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow
- 1 Samory Mashela St., Moscow, 117198, Russia S.P. Botkin City Clinical Hospital
- 5, 2nd Botkinskiy Pr-d., Moscow, 125284, Russia
- Polyclinic № 11, Affiliate № 4, Moscow
- 5 Novatorov St., Moscow, 119421, Russia
- Polyclinic № 201, Affiliate № 1, Zelenograd
- Bldg. 225 Zelenograd, 103305, Russia
- Polyclinic № 68, Moscow
- 22, Bldg. 1 Malaya Yakimanka, Moscow, 119180, Russia
- S.P. Botkin City Clinical Hospital
- Issue: Vol 10, No 1 (2015)
- Pages: 16-23
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 03.06.2015
- URL: https://oncohematology.abvpress.ru/ongm/article/view/134
- DOI: https://doi.org/10.17650/1818-8346-2015-1-16-23
- ID: 134
Cite item
Full Text
Abstract
Efficacy and safety results of rituximab and bendamustine combination (Scheme BR) in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are presented. From 01.2012 to 04.2013, the treatment was initiated in 43 patients (21 with relapses are sensitive to the last line of therapy; 22 – with refractory CLL). Median age at start of therapy was 63.5 years (range from 43 to 81 years). In 40 patients response was evaluated according to NCI-WG criteria (1996). Complete remission (CR) is documented in 5 (12.5 %) cases, partial (PR) or nodular partial remission (nPR) in 17 (42.5 %) cases. MRD-negative CR was achieved in 1 (20.0 %) of 5 patients with CR. With 23.5 months of median follow-up for surviving patients 2-year progression-free survival (PFS) was 47.2 ± 8.5 % (median – 18.5 months), overall survival (OS) – 66.9 ± 7.9 % (median not achieved). Hematological toxicity Grade 3–4 occurred in 15 (34.9 %) cases, same degree infectious complications
in 5 (11.6 %) cases. Patients received 3 or more therapy lines before this treatment (37.5 ± 16.1 % against 74.7 ± 8.3 %; p = 0.016), with «bulky disease» more than 10 cm (0.0 % vs. 75.4 ± 7.5 %; p < 0.001) and received rituximab in combination with chemotherapy in the previous lines, compared to the «naive» cases (44.1 ± 10.5 % against 92.9 ± 6.9 %; p = 0.009) have significantly worsened 2-year OS.
Keywords
About the authors
S. V. Semochkin
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 1 Ostrovityanova St., Moscow, 117997, RussiaFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1 Samory Mashela St., Moscow, 117198, Russia
Author for correspondence.
Email: semochkin_sv@rsmu.ru
Russian Federation
E. G. Arshanskaya
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1 Samory Mashela St., Moscow, 117198, RussiaS.P. Botkin City Clinical Hospital; 5, 2nd Botkinskiy Pr-d., Moscow, 125284, Russia
Russian Federation
O. D. Zakharov
Polyclinic № 11, Affiliate № 4, Moscow; 5 Novatorov St., Moscow, 119421, RussiaRussian Federation
A. N. Kotelnikova
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation
S. S. Kulikova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 1 Ostrovityanova St., Moscow, 117997, RussiaFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
E. V. Ovanesova
Polyclinic № 201, Affiliate № 1, Zelenograd; Bldg. 225 Zelenograd, 103305, RussiaRussian Federation
Yu. B. Kochkareva
Polyclinic № 68, Moscow; 22, Bldg. 1 Malaya Yakimanka, Moscow, 119180, RussiaRussian Federation
V. L. Ivanova
S.P. Botkin City Clinical Hospital; 5, 2nd Botkinskiy Pr-d., Moscow, 125284, RussiaRussian Federation
References
Supplementary files
